Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.666716
Title: Positive allosteric modulators of the strychnine sensitive glycine receptor : a new concept in the treatment of chronic pain
Author: Taylor, Lee
ISNI:       0000 0004 5948 8469
Awarding Body: University of Liverpool
Current Institution: University of Liverpool
Date of Award: 2014
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Thesis embargoed until 01 Aug 2018
Access from Institution:
Abstract:
Chronic pain is a global medical-health problem. It is estimated that approximately 20% of the adult population suffer from some form of chronic pain. Along with the physical and emotional burden that living with chronic pain brings to the individual, there is also a huge socio-economic cost implication currently estimated at more than €200 million per annum in Europe and at over $150 million in the USA. Unfortunately, because of a lack of efficacious treatments, chronic pain is poorly managed. Current therapies for chronic pain act upon well-established targets and have been shown not only to be inadequate for the majority of patients, with only 1 in 4 patients only finding up to 50% relief from their painful syndromes There is, therefore, a continued need for novel analgesic drugs that act at novel therapeutic targets. With the elucidation of the role of α1 glycine receptor (α1 GlyR) plays in nociceptive pathways it has become an attractive target for novel analgesic compounds. Previous work with the group has identified a series of potent bi-phenyl compounds targeting the α1 GlyR with EC50 values in the low nM range. However, these compounds suffered from poor physicochemical and pharmacokinetic properties. Work in this thesis describes the rational design and synthesis of a library of compounds which selectively target the α1 GlyR with EC50 values in the sub nano-molar range. We have successfully progressed from hit to lead stage with improved efficacy and DMPK properties. The lead compound has shown excellent PK profiles, CNS penetration properties and no toxicity issues. We have obtained proof-of concept for the lead compound in a rat model of neuropathic pain and are currently moving forward with lead optimisation.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.666716  DOI: Not available
Keywords: QD Chemistry
Share: